
DA-1726, an obesity and metabolic disorder drug candidate being developed by Dong-A ST and MetaVia, showed greater blood sugar reduction and similar weight loss compared with retatrutide, another obesity drug candidate.
Dong-A ST and MetaVia said Tuesday that they recently presented preclinical study results directly comparing DA-1726 and retatrutide at ObesityWeek 2026, a conference of the American Society for Obesity.
DA-1726 is a new drug candidate being developed as an obesity and metabolic disorder treatment in the oxyntomodulin analog class.
It acts simultaneously on glucagon-like peptide-1 (GLP-1) receptors and glucagon receptors to induce weight loss and blood glucose regulation through appetite suppression, insulin secretion promotion, and increased energy consumption.
Retatrutide, being developed by Eli Lilly, is a triple agonist acting on GLP-1, gastric inhibitory polypeptide (GIP), and glucagon receptors.
This study was conducted to directly compare and evaluate the weight loss, food intake, blood glucose and lipid metabolism improvement effects, and expression of thermogenesis-related genes of DA-1726 and retatrutide in diet-induced obesity (DIO) mice.
Mice were administered DA-1726 at doses of 300 or 500 nmol/kg, and retatrutide at doses of 100 or 200 nmol/kg, subcutaneously twice a week for approximately three weeks.
The high dose was set to be similar to the drug exposure levels when administering DA-1726 48 mg and retatrutide 12 mg to humans, based on pharmacokinetic exposure estimates.
The study results showed that DA-1726 demonstrated a larger blood glucose reduction effect compared to retatrutide. Despite having a relatively lower food intake suppression effect, it showed a similar level of weight loss effect.
The blood glucose reduction rates were 43.0% and 39.2%, respectively, in the DA-1726 low-dose and high-dose administration groups. In contrast, the retatrutide low-dose and high-dose administration groups recorded 21.5% and 32.5%, respectively.
Reflecting the weight changes of the obese control group, the weight loss rates were 34.2% and 41.7%, respectively, in the DA-1726 low-dose and high-dose administration groups, while retatrutide recorded 33.7% and 43.6%, respectively, showing a similar level of weight loss effect.
In contrast, the food intake reduction rates were 19.6% and 31.2%, respectively, in the DA-1726 low-dose and high-dose administration groups, which was lower than retatrutide's 36.7% and 41.4%.
Lipid metabolism improvement effects were also confirmed. The total cholesterol reduction rates were 70.9% and 69.3%, respectively, in the DA-1726 low-dose and high-dose administration groups.
Retatrutide recorded 60.9% and 69.0%, respectively. The LDL cholesterol reduction rates were 89.9% and 88.4% for DA-1726, and 82.8% and 88.1% for retatrutide, respectively.
DA-1726 significantly increased the hepatic expression of the fibroblast growth factor 21 (FGF21) gene, which is involved in lipid and carbohydrate metabolism regulation, with statistical significance. (p<0.05) In the high-dose administration group, hepatic FGF21 protein levels and blood FGF21 levels also increased significantly. (p<0.001)
Compared to retatrutide, DA-1726 more strongly induced the expression of genes related to thermogenesis in brown adipose tissue and browning of white adipose tissue.
Some thermogenesis-related genes showed significantly higher expression than in the high-dose retatrutide administration group. These results suggest the possibility that energy consumption associated with glucagon receptors contributes more significantly to weight loss.
MetaVia CEO Kim Hyeong-heon said that given the company's focus on liver-related metabolic diseases, it is "significant" that the study showed DA-1726 increased hepatic gene expression and protein levels of FGF21, which is involved in lipid and carbohydrate metabolism regulation."
"In particular, despite having a lower food intake suppression effect compared to retatrutide, it showed a larger blood glucose reduction effect and a similar weight loss effect, demonstrating the differentiated metabolic characteristics of DA-1726," Kim said.
He continued, "Based on the liver fat and weight loss effects confirmed in recent clinical trials and the results of this preclinical study, we will prepare to enter Phase 2 clinical trials targeting metabolic dysfunction-associated steatohepatitis with alcohol involvement (MetALD) and alcohol-related liver disease (ALD) in the second half of 2027."